Our flagship ischemic stroke model for testing drugs and devices
Endovascular, porcine model of stroke is our crown jewel. Its quality matches or supersedes other, ethically and logistically challenging canine and primate models of stroke. What sets our model apart is its inducibility inside an MRI scanner, enabling the real-time capture of tissue dynamics and providing an exceptionally precise baseline for subsequent studies. While our primary focus is on imaging, our capabilities extend to behavioral testing, telemetry and post-mortem tissue assessment. This versatility makes our stroke model highly competitive for testing biomarkers, diagnostics, therapeutic agents, and medical devices in a clinically relevant scenario.
Hemorrhagic stroke model
A critical clinical need revolves around tools and strategies for the early diagnostic differentiation between hemorrhagic and ischemic strokes. In response to this imperative, we provide a comprehensive back-to-back comparison of these two stroke models in pigs, serving as a robust platform for the development of devices and the testing of therapeutic strategies.
Other Disease Models And Procedures
Co-founders of Ti-com have an abundant experience with a variety of large and small animal models including multiple sclerosis, amyotrophic lateral sclerosis, brain cancer, Parkinson disease, Alzheimer disease and others. They also mastered various routes of delivery of therapeutic agents to the brain using endovascular route, stereotaxy, convection enhanced delivery, intrathecal, intraventricular and using focused ultrasound. Again, a focus on imaging as a way to follow disease progression and therapeutic agent biodistribution distinct us from many competitors in the field.

How we make it and what is our experience
Over the course of two decades engaged in academic pursuits, we have accumulated a wealth of experience and knowledge.
300 + conference speeches
Passionate about science and rooted in an academic background, we are eager to establish partnerships for multidimensional, international, and interinstitutional demanding projects.
200 + papers
As founders of Ti-com we authored nearly 300 papers published in top tier journals covering various aspects of translational research mainly for applications in neurology and neurooncology
5+ patent applications
As the founders of Ti-com, we have authored nearly 300 papers published in top-tier journals, covering various facets of translational research, primarily focused on applications in neurology and neurooncology.